Mikkael Sekeres, MD, MS, on MDS and Exposure to Agent Orange
ASH 2025
Mikkael Sekeres, MD, MS, Chief, Division of Hematology and Professor of Medicine at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, presents findings from a new study that connects exposure to the herbicide Agent Orange to earlier and more severe cases of myelodysplastic syndromes (MDS). Researchers concluded that exposure is associated with younger age at MDS diagnosis, ultimate MDS diagnosis, genetic complexity of MDS, increased risk of disease progression, and with Black race (Abstract 5626).
The ASCO Post Staff
Anand Patel, MD, of the University of Chicago, discusses results from a phase II trial that showed tyrosine kinase inhibitor plus inotuzumab ozogamicin–based therapy resulted in major molecular response in patients newly diagnosed with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) (Abstract 441).
The ASCO Post Staff
The telomerase inhibitor imetelstat was approved for the treatment of certain patients with lower-risk myelodysplastic syndromes (MDS) based on the results of the phase III IMerge trial. Valeria Santini, MD, of the University of Florence, provides updates on secondary endpoints, including overall and progression-free survival; progression to acute myeloid leukemia; safety; and long-term outcomes by subgroups of interest in IMerge, as well as ad hoc outcomes, including overall survival by response (Abstract 2074).
The ASCO Post Staff
Aaron Gerds, MD, of Cleveland Clinic, reviews results of an evaluation of Synapsis AI, a medically trained, large language model–based end-to-end system, focusing on its accuracy and efficiency in identifying eligible patients for an active phase III polycythemia vera clinical trial (Abstract 4340).
The ASCO Post Staff
Ibrahim Aldoss, MD, of City of Hope, presents findings from a small, single-center study of patients aged 55 years and older with B-cell acute lymphoblastic leukemia (ALL) in first complete remission who were treated with CD19-directed CAR T-cell therapy. Researchers found the therapy was safe, resulted in low-grade adverse events, and led to preliminary durable measurable residual disease response (Abstract 443).
The ASCO Post Staff
Krina Patel, MD, MSc, of The University of Texas MD Anderson Cancer Center, provides updated results from the fully enrolled, ongoing iMMagine-1 phase II registrational trial of anitocabtagene autoleucel, an autologous anti-BCMA CAR T-cell therapy with a novel D-domain binder. The agent is under development for patients with relapsed and/or refractory multiple myeloma (Abstract 256).